Doxorubicin-induced hyperpigmentation

Dermatol Online J. 2008 Oct 15;14(10):18.

Abstract

A 39-year-old man with human immunodeficiency virus infection and Kaposi sarcoma on HAART therapy and doxorubicin presented in 2007 with a hyperpigmented tongue. Physical examination also showed hyperpigmented patches on the mucosal aspects of the lips and longitudinal dark bands on multiple nails. A skin biopsy specimen showed pigmentary alteration. Such hyperpigmentation has been described in numerous case reports and case series and has been reported to resolve within weeks to months of cessation of doxorubicin.

Publication types

  • Case Reports

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Carbamates / therapeutic use
  • Doxorubicin / adverse effects*
  • Doxorubicin / therapeutic use
  • Drug Combinations
  • Furans
  • Humans
  • Lamivudine / therapeutic use
  • Lip Diseases / chemically induced*
  • Male
  • Melanosis / chemically induced*
  • Nails, Malformed / chemically induced*
  • Organophosphates / therapeutic use
  • Ritonavir / therapeutic use
  • Sarcoma, Kaposi / complications
  • Sarcoma, Kaposi / drug therapy*
  • Sulfonamides / therapeutic use
  • Tongue Diseases / chemically induced*
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents
  • Carbamates
  • Drug Combinations
  • Furans
  • Organophosphates
  • Sulfonamides
  • abacavir, lamivudine, and zidovudine drug combination
  • Lamivudine
  • Zidovudine
  • Doxorubicin
  • Ritonavir
  • fosamprenavir